ALISO VIEJO, Calif., May 13 /PRNewswire/ -- Sequent Medical, Inc. announced today that it has closed a $15.6 million Series B venture capital financing. The financing was led by Domain Associates, joined by existing investors Versant Ventures and US Venture Partners. Nimesh Shah of Domain will join Sequent's Board of Directors.
"We are privileged
About Sequent Medical, Inc.
Sequent Medical, Inc. (www.sequentmedical.com) was founded by Bob Rosenbluth, Ph.D. and Brian Cox, with Versant Ventures and US Venture Partners as founding investors. Sequent is dedicated to the development of innovative devices to advance the endovascular treatment of neurovascular disease conditions. Rosenbluth and Cox previously founded MicroVention, Inc., now known as MicroVention Terumo. Sequent has developed proprietary fine wire fabrication technology to create a low porosity device that is deployed within the aneurysm to facilitate occlusion and healing. The market for endovascular treatment of cerebral aneurysms continues to grow rapidly, as improvements in technology, such as the WEB, allow an increasing number of aneurysms to be treated non-surgically.
SOURCE Sequent Medical, Inc.
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All